But only after the company jumps over more regulatory hurdles.
The Biden administration announced Sunday that it will send assistance to India, a country whose COVID-19 daily case rate has exceeded a record-setting 350,000 cases. Reports from the country are horrifying: Many hospitals’ oxygen supply has all but run out, and they are being forced to turn away dying patients. «The United States has identified sources of specific raw material urgently required for Indian manufacture of the Covishield vaccine that will immediately be made available for India,» said National Security Council spokesperson Emily Horne in a press release Sunday. «The U.S. Development Finance Corporation (DFC) is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India, enabling BioE to ramp up to produce at least 1 billion doses of COVID-19 vaccines by the end of 2022.» Now the administration is adding an item to that list. Millions of AstraZeneca doses are currently collecting dust in the U.S. because the regulatory state has refused to approve the vaccine. «The U.S. will begin sharing its entire pipeline of vaccines from AstraZeneca once the COVID-19 vaccine clear federal safety reviews,» the Associated Press reported today after President Joe Biden spoke with Prime Minister Narendra Modi by phone.
